Clinical Comprehensive Evaluation of Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation
Objective:To evaluate the clinical comprehensive value of direct oral anticoagulants(DOACs)in preventing stroke related to non-valvular atrial fibrillation,providing a reference for rational drug use in clinical practice.Methods:Based on the guiding princi-ples of the"A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition)"collect and ana-lyze clinical evidence regarding the use of DOACs for the prevention of stroke in patients with non-valvular atrial fibrillation.The evalua-tion dimensions include efficacy,safety,cost-effectiveness,pharmaceutical characteristics,and other relevant attributes,utilizing a com-prehensive scoring system for quantitative assessment.Results:Among the DOACs included in the analysis,the domestically produced generic rivaroxaban tablets achieved the highest overall score of 77.8 points due to their significant advantages in cost-effectiveness.When analyzing solely from the perspectives of clinical attributes and pharmaceutical characteristics,without considering economic factors,the brand edoxaban tablets performed the best,with a comprehensive score of 65.2 points.Conclusion:As first-line medications for the pre-vention of stroke in patients with non-valvular atrial fibrillation,DOACs present varying advantages.The domestically produced generic rivaroxaban tablets have broad application potential due to their high cost-effectiveness,while the brand edoxaban tablets demonstrate advantages in clinical attributes and pharmaceutical characteristics.Medical institutions should make rational choices regarding the type of DOACs based on the specific conditions of patients,drug accessibility,and cost-effectiveness,to achieve individualized and precise treatment.
万方数据
维普
